Project Grant R01CA296835
Award Date
6/3/25
Completion Date
5/31/30
Dollars Obligated
$728K
Federal Agency
National Cancer Institute
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
New York, USA
Similar Awards
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $205,700.00 to the Sloan-Kettering Institute for Cancer Research to conduct research aimed at addressing the rapid development of resistance to targeted therapies for metastatic colorectal cancer. The research will evaluate how intrinsic tumor features modulate the development of resistance to targeted therapies, and test a novel combination approach of DNA repair inhibition and...
The National Cancer Institute (NCI) awarded a $1,408,844 Project Grant (CFDA 93.395 Cancer Treatment Research) to the Sloan-Kettering Institute for Cancer Research in New York, NY to investigate the theranostic potential of Delta-Like Ligand 3 (DLL3)-targeting agents in high-grade neuroendocrine carcinomas of the lung (small cell lung cancer) and prostate (neuroendocrine prostate cancer). The project aims to utilize a DLL3-targeted radiolabeled monoclonal antibody for non-invasive diagnosis...
This Project Grant award for $267,298.00 from the National Cancer Institute's Cancer Treatment Research program (CFDA 93.395) will support research by the Dana-Farber Cancer Institute, Inc. (DFCI) to investigate targeting the CDK4/6 pathway as a potential therapeutic strategy for translocation renal cell carcinoma (TRCC), an aggressive and rare form of kidney cancer with no established standard of care. The project aims to test the efficacy of CDK4/6 inhibitors, alone or in combination with...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $435,827 to New York University School of Medicine to conduct research aimed at enhancing the efficacy of KRAS inhibitor therapies for cancer treatment. The key focus is to identify synthetic lethal genes and resistance mechanisms that can be targeted to improve outcomes for patients with KRAS-mutated cancers, such as non-small cell lung cancer, colorectal cancer, and pancreatic cancer....
This $176,000 Project Grant awarded by the Department of Defense (DOD) through the Military Medical Research and Development program (CFDA 12.420) supports research by the Sloan-Kettering Institute for Cancer Research to define the biology of and identify therapeutic vulnerabilities in DCK12-inactivated prostate cancer. The award period is from April 1, 2024 to March 31, 2025. As a non-profit organization focused on cancer research and patient care, Sloan-Kettering Institute has previously...
This federal Project Grant award of $2,808,108.00, provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), supports research conducted by the Sloan-Kettering Institute for Cancer Research to investigate the role of clonal hematopoiesis in therapeutic resistance and metastatic relapse in breast cancer. The award period extends from March 1, 2024 to February 29, 2028. Through this funding, the Sloan-Kettering Institute will explore the...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) provides $1,688,087 to the Sanford Burnham Prebys Medical Discovery Institute to conduct research on macropinocytosis inhibition as a strategy to sensitize pancreatic cancer to a glutamine mimetic drug. The key goals are to: (1) examine the role of macropinocytosis as a metabolic adaptation to the glutamine mimetic 6-diazo-5-oxo-L-norleucine (DON) in pancreatic ductal adenocarcinoma (PDAC)...
The federal Project Grant award of $924,001.00 was provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The grant supports research by the Sloan-Kettering Institute for Cancer Research to investigate the cellular and molecular origins of non-small cell lung cancer (NSCLC) brain metastasis. The research aims to enhance understanding of the mechanisms driving NSCLC brain metastasis, with the goal of developing innovative therapeutic...
This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides funding to the Sloan-Kettering Institute for Cancer Research to investigate mechanisms through which deficiency of the SMARCA4 gene promotes metastasis in lung adenocarcinoma. The research aims to elucidate the role of the ROR2/p-GSK3bS9 signaling pathway in driving metastasis in SMARCA4-deficient lung cancer. Key activities include conducting RNA-seq, ChIP-seq, ATAC-seq, and mass...
Sloan-Kettering Institute For Cancer Research was awarded a $796,500 Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) for the period of July 15, 2023 through July 14, 2026. The grant will support research to develop novel tools to improve responses to DNA-damaging therapeutics in metastatic breast cancer. As the prime recipient, Sloan-Kettering Institute For Cancer Research will leverage its expertise in cancer biology,...